{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T19:05:17Z","timestamp":1785351917977,"version":"3.55.0"},"reference-count":46,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,6,25]],"date-time":"2021-06-25T00:00:00Z","timestamp":1624579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinicaltherapeutics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Therapeutics"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.clinthera.2021.06.008","type":"journal-article","created":{"date-parts":[[2021,7,6]],"date-time":"2021-07-06T02:55:28Z","timestamp":1625540128000},"page":"1392-1407.e1","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated Diseases"],"prefix":"10.1016","volume":"43","author":[{"given":"Juliana","family":"Setyawan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andres","family":"Yarur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miriam L.","family":"Zichlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongbo","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine","family":"Fernan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emma","family":"Billmyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathaniel","family":"Downes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassir","family":"Azimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clinthera.2021.06.008_bib0001","first-page":"S11","article-title":"A Brief Review on Immune Mediated Diseases","author":"Adapa","year":"2011","journal-title":"J Clin Cell Immunol"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0002","doi-asserted-by":"crossref","first-page":"3257","DOI":"10.1016\/j.ejca.2012.05.024","article-title":"Incidence, survival and prevalence of myeloid malignancies in Europe","volume":"48","author":"Visser","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0003","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3899\/jrheum.091461","article-title":"Epidemiology of immune-mediated inflammatory diseases: incidence, prevalence, natural history, and comorbidities","volume":"85","author":"El-Gabalawy","year":"2010","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0004","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.it.2012.09.001","article-title":"Immune-mediated disease genetics: the shared basis of pathogenesis","volume":"34","author":"Cotsapas","year":"2013","journal-title":"Trends Immunol"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0005","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1007\/s40259-019-00333-w","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"BioDrugs"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0006","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1136\/pgmj.2006.052688","article-title":"Immune-mediated inflammatory diseases (IMIDs) and biologic therapy: a medical revolution","volume":"83","author":"Kuek","year":"2007","journal-title":"Postgrad Med J"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0007","doi-asserted-by":"crossref","first-page":"k1036","DOI":"10.1136\/bmj.k1036","article-title":"Increased cardiovascular risk in rheumatoid arthritis: mechanisms and implications","volume":"361","author":"England","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0008","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1111\/j.1365-2141.2005.05753.x","article-title":"The interactions between inflammation and coagulation","volume":"131","author":"Esmon","year":"2005","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0009","first-page":"475","article-title":"Direct medical costs of venous thromboembolism and subsequent hospital readmission rates: an administrative claims analysis from 30 managed care organizations","volume":"13","author":"Spyropoulos","year":"2007","journal-title":"J Manag Care Pharm"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0010","unstructured":"Centers for Disease Control and Prevention. 2020 What is Venous Thromboembolism? Available from: https:\/\/www.cdc.gov\/ncbddd\/dvt\/facts.html."},{"key":"10.1016\/j.clinthera.2021.06.008_bib0011","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1016\/j.amepre.2009.12.017","article-title":"Venous thromboembolism: a public health concern","volume":"38","author":"Beckman","year":"2010","journal-title":"Am J Prev Med"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0012","first-page":"e139","article-title":"Heart Disease and Stroke Statistics-2020 Update: A Report From the","volume":"141","author":"Virani","year":"2020","journal-title":"American Heart Association. Circulation"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0013","unstructured":"Kaiser Family Foundation analysis of data from the Centers for Medicare & Medicaid Services. Hospital Compare datasets and Medicare Hospital Quality Chartbook Available from: https:\/\/www.healthsystemtracker.org\/indicator\/quality\/30-day-mortality-following-certain-admissions\/."},{"key":"10.1016\/j.clinthera.2021.06.008_bib0014","first-page":"171","article-title":"Autoimmune diseases and venous thromboembolism: a review of the literature","volume":"2","author":"Zoller","year":"2012","journal-title":"Am J Cardiovasc Dis"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0015","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1136\/heartjnl-2017-311279","article-title":"Association between chronic immune-mediated inflammatory diseases and cardiovascular risk","volume":"104","author":"Baena-Diez","year":"2018","journal-title":"Heart"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0016","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1038\/ajg.2011.63","article-title":"Inflammatory bowel disease is associated with an increased incidence of cardiovascular events","volume":"106","author":"Yarur","year":"2011","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0017","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1001\/archinte.162.10.1182","article-title":"Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology","volume":"162","author":"Tsai","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0018","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1160\/TH11-10-0726","article-title":"Association between cardiovascular disease risk factors and occurrence of venous thromboembolism. A time-dependent analysis","volume":"108","author":"Wattanakit","year":"2012","journal-title":"Thromb Haemost"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0019","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1046\/j.1365-2168.1999.01129.x","article-title":"Deep venous thrombosis in peripheral vascular disease","volume":"86","author":"Libertiny","year":"1999","journal-title":"Br J Surg"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0020","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1007\/s40264-018-0651-5","article-title":"Thromboembolism with Janus Kinase (JAK) Inhibitors for Rheumatoid Arthritis: How Real is the Risk?","volume":"41","author":"Scott","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0021","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/1741-7015-9-1","article-title":"Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases: record-linkage study","volume":"9","author":"Ramagopalan","year":"2011","journal-title":"BMC Med"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0022","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1016\/S0140-6736(11)61306-8","article-title":"Risk of pulmonary embolism in patients with autoimmune disorders: a nationwide follow-up study from Sweden","volume":"379","author":"Zoller","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0023","doi-asserted-by":"crossref","first-page":"I9","DOI":"10.1161\/01.CIR.0000078469.07362.E6","article-title":"Risk factors for venous thromboembolism","volume":"107","author":"Anderson","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0024","doi-asserted-by":"crossref","first-page":"3415","DOI":"10.1001\/archinte.160.22.3415","article-title":"An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study","volume":"160","author":"Samama","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0025","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1001\/archinte.160.6.769","article-title":"Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors","volume":"160","author":"Hansson","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0026","doi-asserted-by":"crossref","first-page":"2402","DOI":"10.1111\/jth.13524","article-title":"The long-term recurrence risk of patients with unprovoked venous thromboembolism: an observational cohort study","volume":"14","author":"Kyrle","year":"2016","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0027","doi-asserted-by":"crossref","first-page":"2046","DOI":"10.1161\/STROKEAHA.117.016815","article-title":"One-Year Incidence, Time Trends, and Predictors of Recurrent Ischemic Stroke in Sweden From 1998 to 2010: An Observational Study","volume":"48","author":"Bergstrom","year":"2017","journal-title":"Stroke"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0028","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1111\/j.1538-7836.2011.04254.x","article-title":"Residual vein obstruction to predict the risk of recurrent venous thromboembolism in patients with deep vein thrombosis: a systematic review and meta-analysis","volume":"9","author":"Carrier","year":"2011","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0029","first-page":"120","article-title":"Risk factors for venous and arterial thrombosis","volume":"9","author":"Previtali","year":"2011","journal-title":"Blood Transfus"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0030","first-page":"451","article-title":"Assessing the risk of recurrent venous thromboembolism\u2013a practical approach","volume":"11","author":"Fahrni","year":"2015","journal-title":"Vasc Health Risk Manag"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0031","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1210\/jc.2012-4070","article-title":"Where are we 10 years after the Women's Health Initiative?","volume":"98","author":"Lobo","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0032","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1097\/AOG.0b013e31827a08c8","article-title":"Lessons learned from the Women's Health Initiative trials of menopausal hormone therapy","volume":"121","author":"Rossouw","year":"2013","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0033","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1136\/bmj.39555.441944.BE","article-title":"Hormone replacement therapy and risk of venous thromboembolism in postmenopausal women: systematic review and meta-analysis","volume":"336","author":"Canonico","year":"2008","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0034","doi-asserted-by":"crossref","first-page":"k4810","DOI":"10.1136\/bmj.k4810","article-title":"Use of hormone replacement therapy and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases","volume":"364","author":"Vinogradova","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0035","article-title":"Combined oral contraceptives: venous thrombosis","volume":"3","author":"de Bastos","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0036","doi-asserted-by":"crossref","first-page":"E1319","DOI":"10.1503\/cmaj.110463","article-title":"Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study","volume":"183","author":"Gronich","year":"2011","journal-title":"CMAJ"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0037","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1055\/s-0036-1579642","article-title":"Thrombosis in Autoimmune Diseases: A Role for Immunosuppressive Treatments?","volume":"42","author":"Silvestri","year":"2016","journal-title":"Semin Thromb Hemost"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0038","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ecco-jcc\/jjx162","article-title":"Steroid but not biological therapy elevates the risk of venous thromboembolic events in inflammatory bowel disease: a meta-analysis","volume":"12","author":"Sarlos","year":"2018","journal-title":"J Crohns Colitis"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0039","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1001\/jamainternmed.2013.122","article-title":"Use of glucocorticoids and risk of venous thromboembolism: a nationwide population-based case-control study","volume":"173","author":"Johannesdottir","year":"2013","journal-title":"JAMA internal medicine"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0040","unstructured":"U.S. Food and Drug Administration. FDA approves boxed warning about increased risk of blood clots and death with higher dose of arthritis and ulcerative colitis medicine tofacitinib (Xeljanz, Xeljanz XR). Available from: https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-approves-boxed-warning-about-increased-risk-blood-clots-and-death-higher-dose-arthritis-and."},{"key":"10.1016\/j.clinthera.2021.06.008_bib0041","unstructured":"Upadacitinib Cross-Discipline Team Leader, Review Division Director Summary, Office Director Summary, accessed at https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2019\/211675Orig1s000SumR.pdf. In: Center for drug evaluation and research, editor."},{"key":"10.1016\/j.clinthera.2021.06.008_bib0042","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3899\/jrheum.171361","article-title":"Safety profile of baricitinib in patients with active rheumatoid arthritis with over 2 years median time in treatment","volume":"46","author":"Smolen","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0043","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s40264-017-0622-2","article-title":"Analysis of Spontaneous Postmarket Case Reports Submitted to the FDA Regarding Thromboembolic Adverse Events and JAK Inhibitors","volume":"41","author":"Verden","year":"2018","journal-title":"Drug Saf"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0044","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s40266-020-00775-w","article-title":"Safety of Janus Kinase Inhibitors in Older Patients: A Focus on the Thromboembolic Risk","volume":"37","author":"Rajasimhan","year":"2020","journal-title":"Drugs Aging"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0045","doi-asserted-by":"crossref","first-page":"1042","DOI":"10.1002\/art.40841","article-title":"Cardiovascular Safety During Treatment With Baricitinib in Rheumatoid Arthritis","volume":"71","author":"Taylor","year":"2019","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.clinthera.2021.06.008_bib0046","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1001\/jamacardio.2018.4537","article-title":"Cardiovascular Risk Factors Associated With Venous Thromboembolism","volume":"4","author":"Gregson","year":"2019","journal-title":"JAMA Cardiol"}],"container-title":["Clinical Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002393?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0149291821002393?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T08:55:15Z","timestamp":1758963315000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0149291821002393"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":46,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0149291821002393"],"URL":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.06.008","relation":{},"ISSN":["0149-2918"],"issn-type":[{"value":"0149-2918","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risk of Thromboembolic Events and Associated Risk Factors, Including Treatments, in Patients with Immune-mediated Diseases","name":"articletitle","label":"Article Title"},{"value":"Clinical Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clinthera.2021.06.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}